SGIOY News and Press, Shionogi & Co. Ltd. ADR From 08/01/23

2023-08-01 13:32:44 ET More on Daiichi Sankyo Daiichi Sankyo Company, Limited ( OTCPK:DSKYF ) Q1 2023 Earnings Call Transcript Shionogi & Co., Ltd. ( OTCPK:SGIOF ) Q1 2023 Earnings Call Transcript Daiichi Sankyo: There Is A Lot Of Room To Grow Dai...

2023-05-14 22:31:09 ET Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Conference Call May 10, 2023, 10:00 PM ET Company Participants Yoshimasa Kyokawa - Investor Relations Isao Teshirogi - Chairman and CEO John Keller - Executive Officer, the General Manager o...

2023-03-30 12:05:56 ET A federal judge on Thursday struck down a key provision in the Affordable Care Act (ACA) that requires health plans to provide free coverage for preventive care, including pre-exposure prophylaxis drugs for HIV (PrEP) and cancer screenings. District Court Judg...

2023-03-30 05:13:16 ET The United Nations-backed Medicines Patent Pool (MPP) signed agreements with Aurobindo, Cipla and Viatris ( NASDAQ: VTRS ) to produce generic versions of ViiV Healthcare's long-acting HIV prevention medicine. ViiV — which is majority o...

Summary Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside. However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit an...

Shionogi ( OTCPK:SGIOY ) CEO Isao Teshirogi expects that assuming it wins US regulatory approval, the Japanese pharma's COVID-19 pill Xocova (ensitrelvir) will lead to $2B in annual sales. Speaking with Reuters, Teshirogi said that Xocova's US FDA approval could come in the wint...

Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and Accounting Department Ryuichi Kiyama - Senior Executive Officer and Seni...

Shionogi ( OTCPK:SGIOF ) ( OTCPK:SGIOY ) said its oral COVID-19 drug S-217622 helped patients achieve resolution of five Omicron-related symptoms faster, compared to placebo, thereby meeting the main goal of a phase 3 part of a phase 2/3 study conducted i...

Shionogi & Co., Ltd. (SGIOF) Q1 2022 Earnings Conference Call August 1, 2022 01:45 ET Company Participants Yoshimasa Kyokawa - Investor Relations John Keller - Senior Executive Officer and Senior Vice President, R&D Supervisory Unit Toshinobu Iwasaki - Se...

Shionogi & Co. press release ( OTCPK:SGIOF ): Q1 GAAP EPS of ¥115.13. Revenue of ¥71.84B (+4.2% Y/Y). For further details see: Shionogi & Co. GAAP EPS of ¥115.13, revenue of ¥71.84B